Apyx Medical Corporation (APYX) Q2 2025 Earnings Call Transcript

Apyx Medical (APYX) reported Q2 2025 revenue of $11.4 million, a 6% year-over-year decline primarily due to an anticipated strategic reduction in OEM sales, but significantly narrowed its net loss to $3.8 million ($0.09/share) and improved adjusted EBITDA loss to $2 million, reflecting successful cost reduction initiatives. Driven by exceptional early interest and pre-sales for its new AYON integrated body contouring system, which sees full commercial launch in September, the company raised its full-year 2025 revenue guidance to $50-$52 million. Management highlighted AYON and the Renuvion platform's strong positioning to capitalize on growing aesthetic procedure demand, particularly from patients using GLP-1 medications, and expects international expansion, including the recent China launch, to be a key growth driver.

Analysis

Apyx Medical Corporation reported a 6% year-over-year revenue decline in Q2 2025 to $11.4 million, a result that was anticipated and driven by a strategic 29% reduction in OEM segment sales. The core Advanced Energy segment remained stable at $9.7 million, with a modest domestic dip in handpiece volume attributed to sales reps focusing on pre-sales for the new AYON system. More significantly, the company demonstrated substantial operational improvement following its November 2024 restructuring. Operating expenses decreased by $3.3 million, leading to a 54% reduction in both the operating loss (to $2.6 million) and the adjusted EBITDA loss (to $2.0 million). Net loss per share narrowed significantly to $0.09 from $0.19 in the prior-year period. This financial discipline has reduced cash used in operations from $4.3 million to $1.2 million, and management projects its current cash of $29.3 million is sufficient to fund operations through 2027. The outlook is decidedly positive, underpinned by better-than-expected pre-orders for its new all-in-one AYON system, which is launching in September. This strong early demand prompted management to raise full-year 2025 revenue guidance to a range of $50-$52 million, up from $47.6-$49 million, signaling confidence that AYON's launch can overcome the broader market's subdued capital spending. The company also highlighted its Renuvion technology's strategic position to capture demand from the growing GLP-1 patient population and its recent entry into the Chinese market as key long-term growth drivers.

Key Decisions for Investors

• Investors should view the significant full-year revenue guidance increase, driven by strong AYON system pre-orders, as a primary bullish catalyst that could accelerate growth in the second half of 2025.
• Consider the company's improved financial health, evidenced by a 54% reduction in adjusted EBITDA loss and decreased cash burn, which provides a stable foundation for its aggressive commercial launches in the U.S. and China.
• Monitor the initial sales ramp of the AYON system post-September launch and early revenue contribution from the new China distribution partnership as key indicators of the company's ability to execute on its long-term growth strategy.
• The strategic positioning of the Renuvion platform to address skin laxity in the rapidly expanding GLP-1 patient population represents a substantial market opportunity that warrants close attention.